Fatal outcome of a hypersensitivity reaction to paclitaxel: A critical review of premedication regimens

British Journal of Cancer

Volumn 90, Issue 2, 2004, Pages 304-305

  Kloover, J S ^a   Den Bakker, M A ^b   Gelderblom, H ^c   Van Meerbeeck, J P ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anaphylaxis; Dexamethasone; Hypersensitivity reaction; Paclitaxel; Premedication

Indexed keywords

CARBOPLATIN; CLEMASTINE; DEXAMETHASONE; PACLITAXEL; RANITIDINE;

ADULT; ASSISTED VENTILATION; AUTOPSY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG HYPERSENSITIVITY; DRUG INFUSION; DYSPNEA; HEART ARREST; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERSENSITIVITY REACTION; INTUBATION; LOW BACK PAIN; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM METASTASIS; PLEURA METASTASIS; PREMEDICATION; PRIORITY JOURNAL; RESUSCITATION; REVIEW; SHORT COURSE THERAPY; THORAX PAIN;

EID: 84934851038     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601303     Document Type: Review

References (17)

1. Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF (1997) Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 8: 611-614
2. Dye D, Watkins J (1980) Suspected anaphylactic reaction to Cremophor EL. BMJ 280: 1353
3. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle delection for drug formulation. Eur J Cancer 37: 1590-1598
4. Kintzel PE (2001) Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother 35: 1114-1117
5. Koppler H, Heymanns J, Weide R (2001) Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie 24: 283-285
6. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos Ch, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos Th, Tsavdaridis D, Papakostas P, Bacoyiannis Ch, Dimopoulos M (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20: 3578-3585
7. Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, Trim K (2002) A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 84: 420-425
8. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J (1999) An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 125: 427-429
9. Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV (1998) Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol 69: 122-124
10. O'Sullivan BT, Cutler DJ, Hunt GE, Walters C, Johnson GF, Catherson ID (1997) Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. Biol Psychiatry 41: 574-584
11. Parikh B, Khanolkar S, Advani SH, Dhabhar B, Chandra M (1996) Safety profile of single-dose dexamethasone premedication for paclitaxel. J Clin Oncol 14: 2189-2190
12. Pumphrey RSH, Roberts ISO (2000) Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 53: 273-276
13. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332: 1004-1014
14. Szebeni J, Alving CR, Savay S (2001) Formation of complement-activating particles in aqueous solutions of taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 1: 721-735
15. Weiss RB, Baker Jr JR (1987) Hypersensitivity reactions from antineoplastic agents. Cancer Metast Rev 6: 413-432
16. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263-1268
17. Zanotti KM, Markman M (2001) Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 24: 767-779